ReviewInternational journal of molecular sciences2020
Deciphering SARS-CoV-2 Virologic and Immunologic Features.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Long-term impact of COVID-19 in patients with lung cancer receiving immune checkpoint inhibitors: a multicenter cohort study during Omicron pandemic.BMC infectious diseases · 2025Article
- Co-Infections and Their Prognostic Impact on Melioidosis Mortality: A Systematic Review and Individual Patient Data Meta-Analysis.Epidemiologia (Basel, Switzerland) · 2025Review
- Viral Transmission in Sea Food Systems: Strategies for Control and Emerging Challenges.Foods (Basel, Switzerland) · 2025Review
- Gut microbiome dysbiosis and inflammatory markers in severe COVID-19: links to atherosclerosis and potential therapeutic insights.Gastroenterology and hepatology from bed to bench · 2025Article
- Review
- Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.Cell communication and signaling : CCS · 2023Review
- Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks.Frontiers in microbiology · 2023Review
- The impact of immune dysfunction on perioperative complications in surgical COVID-19 patients: an imperative for early immunonutrition.Patient safety in surgery · 2022Article
- Evaluating immunohaematological profile among COVID-19 active infection and recovered patients in Ghana.PloS one · 2022Article
- NK cells in SARS-CoV-2 infection.Central-European journal of immunology · 2022Review
- Endocytosis of abiotic nanomaterials and nanobiovectors: Inhibition of membrane trafficking.Nano today · 2021Review
- Mitochondria and Mitochondrial DNA: Key Elements in the Pathogenesis and Exacerbation of the Inflammatory State Caused by COVID-19.Medicina (Kaunas, Lithuania) · 2021Review
- Molecular Communications in Viral Infections Research: Modeling, Experimental Data, and Future Directions.IEEE transactions on molecular, biological, and multi-scale communications · 2021Article
- Classical and alternative receptors for SARS-CoV-2 therapeutic strategy.Reviews in medical virology · 2021Review
- Molecular Dynamics Studies on the Structural Characteristics for the Stability Prediction of SARS-CoV-2.International journal of molecular sciences · 2021Review
- Review
- Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors.Practical laboratory medicine · 2021Article
- Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry InhibitorFrontiers in microbiology · 2021Article
- Computer-aided discovery, design, and investigation of COVID-19 therapeutics.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 and its associated pathology, COVID-19, have been of particular concerns these last months due to the worldwide burden they represent. The number of cases requiring intensive care being the critical point in this epidemic, a better understanding of the pathophysiology leading to these severe cases is urgently needed. Tissue lesions can be caused by the pathogen or can be driven by an overwhelmed immune response. Focusing on SARS-CoV-2, we and others have observed that this virus can trigger indeed an immune response that can be dysregulated in severe patients and leading to further injury to multiple organs. The purpose of the review is to bring to light the current knowledge about SARS-CoV-2 virologic and immunologic features. Thus, we address virus biology, life cycle, tropism for many organs and how ultimately it will affect several host biological and physiological functions, notably the immune response. Given that therapeutic avenues are now highly warranted, we also discuss the immunotherapies available to manage the infection and the clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.